JP2024514098A5 - - Google Patents
Info
- Publication number
- JP2024514098A5 JP2024514098A5 JP2023560644A JP2023560644A JP2024514098A5 JP 2024514098 A5 JP2024514098 A5 JP 2024514098A5 JP 2023560644 A JP2023560644 A JP 2023560644A JP 2023560644 A JP2023560644 A JP 2023560644A JP 2024514098 A5 JP2024514098 A5 JP 2024514098A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110358192 | 2021-04-01 | ||
| CN202110358192.3 | 2021-04-01 | ||
| PCT/CN2022/084650 WO2022206929A1 (zh) | 2021-04-01 | 2022-03-31 | 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024514098A JP2024514098A (ja) | 2024-03-28 |
| JP2024514098A5 true JP2024514098A5 (https=) | 2024-04-11 |
| JPWO2022206929A5 JPWO2022206929A5 (https=) | 2024-04-11 |
Family
ID=83458071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560644A Pending JP2024514098A (ja) | 2021-04-01 | 2022-03-31 | ＥｒｂＢ２突然変異体を標的とする阻害薬の調製における化合物の使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240197737A1 (https=) |
| EP (1) | EP4316491A4 (https=) |
| JP (1) | JP2024514098A (https=) |
| CN (1) | CN115192580A (https=) |
| WO (1) | WO2022206929A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| CN116606289B (zh) * | 2022-02-17 | 2026-02-24 | 上海医药集团股份有限公司 | 一种含氮杂环化合物的晶型、制备方法及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007095038A2 (en) * | 2006-02-09 | 2007-08-23 | Novartis Ag | Mutations and polymorphisms of erbb2 |
| JP6791979B2 (ja) | 2016-03-01 | 2020-11-25 | シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド | 含窒素ヘテロ環化合物、製造方法、中間体、組成物及び応用 |
| EP3677583A4 (en) * | 2017-09-01 | 2021-07-21 | Shanghai Pharmaceuticals Holding Co., Ltd. | NITROGENOUS HETEROCYCLIC COMPOUND, METHOD OF PREPARATION, INTERMEDIATE, COMPOSITION AND APPLICATION |
| EP3946293A4 (en) * | 2019-03-29 | 2023-05-03 | Board of Regents, The University of Texas System | COMPOUNDS WITH ANTITUMORIC ACTIVITIES AGAINST CANCER CELLS WITH EGFR OR HER2 EXON 20 INSERTATIONS |
-
2022
- 2022-03-31 JP JP2023560644A patent/JP2024514098A/ja active Pending
- 2022-03-31 US US18/284,162 patent/US20240197737A1/en active Pending
- 2022-03-31 EP EP22779109.2A patent/EP4316491A4/en active Pending
- 2022-03-31 WO PCT/CN2022/084650 patent/WO2022206929A1/zh not_active Ceased
- 2022-03-31 CN CN202210356800.1A patent/CN115192580A/zh active Pending